tldrdaily.news logo
Tag

Obesity Drugs

All articles tagged with #obesity drugs

GLP-1 obesity drugs and pancreatitis: what the science actually shows
health4 days ago

GLP-1 obesity drugs and pancreatitis: what the science actually shows

Regulators in the UK and Brazil warned of a possible link between GLP-1 weight‑loss drugs and pancreatitis, but causality remains unclear. With millions using GLP-1 therapies for obesity and related conditions, reported pancreatitis cases and deaths are very rare relative to use (UK: 19 pancreatitis deaths since 2007 and about 1,300 related reports among ~1.6 million users; Brazil: 6 deaths and 145 pancreatitis cases since 2020). Meta-analyses yield mixed results—some show a small risk, others none—while a large real‑world study found no difference in pancreatitis between GLP‑1 users and non‑users with similar risk factors. Ongoing pharmacovigilance and rigorous studies are needed to distinguish true signals from background risk.

via Nature|
#clinical-trials#glp-1#health
TrumpRx: White House rolls out cash-pay drug hub to lower costs
politics20 days ago

TrumpRx: White House rolls out cash-pay drug hub to lower costs

The White House announced TrumpRx, a direct-to-consumer hub that directs cash-paying patients to discounts offered by drugmakers on their own sites, as part of efforts to lower U.S. prescription costs. The site does not sell drugs itself and may not benefit insured patients who rely on coverage, but could help uninsured or underinsured access drugs not widely covered, such as obesity medications; participating makers include Lilly and Novo Nordisk, with prices advertised (e.g., Ozempic and Wegovy at about $350/month) amid broader debated savings, since actual prices often depend on rebates and payer contracts. The overall impact on out-of-pocket costs remains uncertain.

via CNBC|
#direct-to-consumer#discounts#drug-pricing
Medicare tailwinds could accelerate Lilly’s obesity-pill rollout
business26 days ago

Medicare tailwinds could accelerate Lilly’s obesity-pill rollout

Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.

via CNBC|
#business#eli-lilly#glp-1
Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs
business26 days ago

Lilly bets on a $3.5B PA plant to accelerate next-gen obesity drugs

Eli Lilly announced a $3.5 billion manufacturing plant in Pennsylvania’s Lehigh Valley to produce its next-generation obesity therapies, including the experimental drug retatrutide. The new facility, Lilly’s fourth major U.S. site, is slated to start this year and become operational in 2031, creating about 850 local jobs and 2,000 construction roles, as the company seeks to expand capacity amid strong GLP-1 market competition and ongoing push to secure drug supply.

via CNBC|
#business#eli-lilly#glp-1
Pfizer and Novo Nordisk's $10 Billion Battle Reshapes Biotech M&A
business3 months ago

Pfizer and Novo Nordisk's $10 Billion Battle Reshapes Biotech M&A

Pfizer's $10 billion acquisition of Metsera, a company developing experimental weight loss drugs, highlights significant activity in biotech mergers and investments, with venture funds like Population Health Partners and ARCH Venture Partners poised to profit greatly. The deal underscores both opportunities and cautionary lessons in biotech M&A and investment strategies.

via statnews.com|
#biotech-manda#business#metsera
Pfizer's $10 Billion Bet on Metsera Sparks Market Uncertainty
business3 months ago

Pfizer's $10 Billion Bet on Metsera Sparks Market Uncertainty

Pfizer has acquired Metsera for up to $10 billion in a high-stakes deal to enter the obesity treatment market, aiming to recover from past struggles in this sector and boost its declining COVID-19 vaccine sales. The success of the investment remains uncertain, with Pfizer CEO Albert Bourla acknowledging the risk of overpaying if the venture fails or gaining a significant advantage if it succeeds.

via statnews.com|
#acquisition#business#metsera
Pfizer Acquires Metsera in $10 Billion Obesity Drug Deal
business3 months ago

Pfizer Acquires Metsera in $10 Billion Obesity Drug Deal

Novo Nordisk's CEO Mike Doustdar withdrew from a $10 billion bid for Metsera after Pfizer matched its offer, highlighting intense competition in the obesity drug market. Despite setbacks, Novo plans to pursue other acquisitions and focus on its pipeline, including new treatments and potential breakthroughs like a pill form of semaglutide. The company is shifting towards a more aggressive, market-driven approach to regain its leadership in the booming weight-loss industry.

via Bloomberg.com|
#business#manda-strategy#metsera